Vaccibody AS announced the appointments of Mikkel Wandahl Pedersen as new Chief Scientific Officer (CSO) and Agnete B. Fredriksen as Chief Innovation & Strategy Officer. Mikkel Wandahl Pedersen comes to Vaccibody from a position as CSO of Symphogen. In her role as Chief Innovation & Strategy Officer, Agnete B. Fredriksen's responsibilities will include both the Strategy and Business Development areas. In addition, Agnete B. Fredriksen will prioritize maintaining Vaccibody's external scientific relations as well as the dialogue with international specialist investors and equity analysts. Agnete B. Fredriksen have already for several years spent a significant amount of her time in the above areas which have grown in both significance and volume in connection with the growth of the company. Mikkel Wandahl Pedersen and Agnete B. Fredriksen will commence their roles at Vaccibody on June 1, 2021, and both will report to Michael Engsig, Chief Executive Officer.